CMS Administrator Mehmet Oz, speaking at a Medicare Advantage industry event, described the program as a garden that has become 'vulnerable to weeds and overgrowth,' with patients paying the price financially and physically. His comments, reported by Healthcare Dive, are the latest indication that the Trump administration is still focused on tightening oversight of the privatized Medicare plans.
The stakes are high: the U.S. is projected to spend $76 billion more on Medicare Advantage this year than it would on traditional Medicare, partly because insurers exaggerate the severity of members' illnesses to boost payments. Plans have also faced criticism for narrow networks and prior authorization hurdles that can delay care.
Yet the administration's actions have been mixed. It finalized higher 2027 payment rates after an insurer lobbying push and reverted to a more generous quality ratings system, but it also finalized guardrails on risk adjustment and stepped up audits for overpayments. Oz's garden metaphor, while colorful, underscores a policy tension between defending a popular program and reining in its costs.